In June 2025, MBX Biosciences announced that it has submitted an IND application to the FDA for MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug targeting obesity, which received regulatory clearance in July
Transf Clinique et Biologique
4) Common healthy traps swaps fruit drinks/iced teas/energy drinks water, sparkling water, unsweetened tea/coffee granola/cereal bars plain yogurt + fruit, nuts, or a simple sandwich flavored yogurt plain + fruit/cinnamon fit cookies/protein snacks eggs, dairy, nuts, beans, minimally processed proteins #publichealth #healtheducation #healthpromotion #preventivehealth #evidencebased #healthliteracy #nutrition #labelreading #ultraprocessedfoods #addedsugar #wholefoods #realfood #metabolichealth #cardiometabolichealth #lifestylemedicine #hearthealth #diabetesprevention #communityhealth To view or add a comment, sign in NEW U.S
GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound have become powerful tools for treating type 2 diabetes and obesity
Respuesta Rpida: Los agonistas GLP-1 no tratan problemas de tiroides y estn contraindicados en pacientes con historia personal o familiar de carcinoma medular de tiroides o neoplasia endocrina mltiple tipo 2